Chong Kun Dang and Menagen sign agreement for Nesbell® (biosimilar darbepoetin alfa)

Jul 5, 2021

Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar darbepoetin alfa). Under the agreement, Chong Kun Dang will receive a down payment and milestone payments in exchange for exclusive commercialisation rights in Oman, Saudi Arabia, UAE, Kuwait Qatar and Bahrain.

Print Page Mail Article